Dr. Govindarajan’s laboratory is interested in understanding and overcoming drug resistance in pancreatic cancer. His training is in the areas of animal sciences, cancer biology and drug transport-based pharmacokinetics, and has extensively used cell and animal models to evaluate nucleoside and oligonucleotide therapies. He also developed several new insights into the pharmacology and cytotoxicity of nucleoside analog drugs. Current focuses in his laboratory are to understand the epigenetic alterations in pancreatic cancer and to evaluate novel epigenetic reversal agents for effective pancreatic cancer treatment. Understanding epigenetic regulation of pluripotent stem cell factors in microRNA biogenesis is also of interest.
- Postdoc - University of Washington, Seattle, WA
- PhD - University of Nebraska Medical Center, Omaha, NE
- MVSc - Indian Veterinary Research Institute, India
- BVSc - Madras Veterinary College, TANUVAS, India
- Research Scholar, 2015 - 2019
- Guest Editor, 2015 - 2015
- 2015 Reviewer, 2015 - 2015
- Elected member, 2014 - 2017
- 2013 Reviewer, 2013 - 2013
- View all honors
- Muruganandan S, Govindarajan R, Sinal CJ. Bone Marrow Adipose Tissue and Skeletal Health. Curr Osteoporos Rep. 2018 Aug;16(4):434-442.
- Muruganandan S, Govindarajan R, McMullen NM, Sinal CJ. Chemokine-Like Receptor 1 Is a Novel Wnt Target Gene that Regulates Mesenchymal Stem Cell Differentiation. Stem Cells. 2017 03;35(3):711-724.
- Mody HR, Hung SW, AlSaggar M, Griffin J, Govindarajan R. Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p. Mol Cancer Res. 2016 11;14(11):1124-1135.